Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 7/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039259 | 0.93 | LRRK2 (0.47) | EGFRLRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2203187 | 0.88 | NPC1 (0.46) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL12259280 | 0.88 | LRRK2 (0.47) | EGFRLRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2202126 | 0.82 | DYRK3 (0.48) | EGFRLRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL4035683 | 0.82 | DYRK3 (0.48) | MEN1NPC1RAB9AKMT2ALRRK2 | |
| SCHEMBL4035491 | 0.80 | PRKD1 (0.45) | EGFRLRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2229449 | 0.78 | TGFBR1 (0.56) | EGFRLRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2202465 | 0.77 | EGFR (0.61) | EGFRTGFBR1PRKD1 | |
| SCHEMBL2197137 | 0.74 | TGFBR1 (0.50) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL4035611 | 0.72 | LRRK2 (0.47) | LRRK2RIPK2RIPK3TGFBR1PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | MEN1 3928/4885NPC1 4689/4885RAB9A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.